BPS 2018

XeriSol Formulation Technology for Stable Peptide Injectables

Steven Prestrelski

Chief Scientific Officer, Xeris Pharmaceuticals, Inc.

ABSTRACT

The XeriSol™ formulation technology platform is specifically designed to produce optimal stability and solubility with peptide-based drugs through proprietary formulation in biocompatible, non-aqueous solvents. The XeriSol platform can achieve high solubility and room temperature stability for peptide drugs currently encountering formulation challenges. Xeris’s platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage drugs and biologics. In particular, XeriSol™ offers the opportunity to:
• Eliminate reconstitution
• Enable long-term room-temperature stability
• Significantly reduce injection volume
• Eliminate the requirement for IV infusion – convert to subcutaneous injection or infusion drugs that previously required large-volume IV administration
• Enable co-delivery/co-formulation of active pharmaceutical ingredients
We have a strong global patent position for both XeriSolâ„¢ providing patent protection out to 2036.

BIO

Dr. Steve Prestrelski is the Founder and Chief Scientific Officer of Xeris Pharmaceuticals, Inc., a company focused on creating enhanced injectable formulations based on proprietary non-aqueous formulation platforms. He has worked in the biopharmaceutical and drug delivery industries for >25 years with companies such as Amgen, Alza, PowderJect and Amylin. Steve has an BS degree in Nutrition Science from Drexel University, a PhD in biophysics from City University of New York and an MBA from the Rady School of Management at UC San Diego.

Information for BPS Presenters

The Boulder Peptide Foundation was established to further the science and knowledge of peptide technology to develop novel therapeutics, biomaterials, medical diagnostics and other beneficial uses for mankind. As part of this goal we run several programs to support career advancement, seminars and educational events. Join us on our mission to expand the applications of peptide science.

Information for BPS Presenters

The purpose of the Boulder Peptide Symposium is to encourage sharing of information related to peptide therapeutic development with an emphasis on the technical, scientific and regulatory aspects of the pharmaceutical development. Presentations that demonstrate original thinking or share experiences from case studies in product development shall receive priority over others.

The Boulder Peptide Symposium offers multiple opportunities for participants to present.

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.

Refund Policy - Terms and Conditions - Privacy Policy